Brief: Addex Therapeutics Starts Phase 2B/3 Study With Dipraglurant For Dyskinesia
29/06/2021 06:04
June 29 (Reuters) - ADDEX THERAPEUTICS LTD ADXN.S :
* ADDEX THERAPEUTICS INITIATES PIVOTAL PHASE 2B/3 STUDY WITH
DIPRAGLURANT FOR DYSKINESIA ASSOCIATED WITH PARKINSON’S DISEASE
Source text for Eikon: ID:nGNE4ll13m
Further company coverage: ADXN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Addex Therapeutics
See all newsBrief: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies Of NTX-253 For Schizophrenia
NASDAQ RESUMED AT 11:29 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:24 AM
Switzerland's Addex Therapeutics Q2 net loss narrows on decline in R&D expenses
Brief: Addex Therapeutics Q2 Operating Income CHF -645 Thousand